Hansoh Pharmaceutical Group's (HKG:3692) innovative drug Ameile has obtained drug registration approval from China's National Medical Products Administration for a third indication.
The new indication is for the treatment of patients with locally advanced, unresectable non-small cell lung cancer, a Monday filing with the Hong Kong bourse said.